创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

GE Wenxin, ZHANG Lei, QI Lianwen. Progress of Neuraminidase 1 in Cardiovascular Diseases[J]. Progress in Pharmaceutical Sciences, 2023, 47(12): 884-896. DOI: 10.20053/j.issn1001-5094.2023.12.002
Citation: GE Wenxin, ZHANG Lei, QI Lianwen. Progress of Neuraminidase 1 in Cardiovascular Diseases[J]. Progress in Pharmaceutical Sciences, 2023, 47(12): 884-896. DOI: 10.20053/j.issn1001-5094.2023.12.002

Progress of Neuraminidase 1 in Cardiovascular Diseases

  • Cardiovascular disease (CVD) is one of the major global health threats, with increasing morbidity and mortality rates, posing a heavy economic and social burden in China. Neuraminidases (NEU) are a class of enzymes that hydrolyze cell surface sialic acid. Among them, neuraminidase-1(NEU1) plays an important role in the regulation of various metabolic and signaling pathways in the progression of CVD. This article provides an overview of the progress of NEU1 research in a variety of cardiovascular diseases, including its mechanisms of action. It also summarizes the current research status of NEU1 inhibitors, aiming to provide a basis and direction for future research on NEU1 in CVD.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return